New data on CYTOMIMIC Technology's potential to stimulate tissue repair featured at 69th AAD

Johnson & Johnson Consumer Companies, Inc. today announced that its award-winning, breakthrough CYTOMIMIC™ Technology will be featured in a scientific poster at the 69th Annual Meeting of the American Academy of Dermatology (AAD), February 4-8, 2011, at the Ernest N. Morial Convention Center in New Orleans, LA. This esteemed, award-winning, innovative technology from Johnson & Johnson Consumer Companies, Inc. comes from decades of research to harness the power of bioelectricity to improve skin rejuvenation.

"Just one year after the unveiling of CYTOMIMIC™ Technology for use in anti-aging at this prestigious forum, we are excited to present new clinical data on its potential to stimulate tissue repair," says Dr. Ying Sun, a Distinguished Research Fellow and Science Leader at Johnson & Johnson Consumer Companies, Inc. "Injured skin naturally generates a low level electrical signal to promote healing. The application of CYTOMIMIC™ technology has clinically demonstrated the ability to mimic this healing signal for potential tissue healing and rejuvenation applications."

The poster "Biomimetic Signaling Technology Mimics Healing Current in Skin" will be displayed as electronic poster #P1604 in the E-Poster Exhibit.  It will be the 10th poster on CYTOMIMIC™ Technology accepted and displayed at the Annual Meeting of the AAD, joining the nine posters that marked the technology's debut last year. The poster will be one of 28 posters on display from the beauty care division of Johnson & Johnson Consumer Companies, Inc. CYTOMIMIC™ Technology will also be featured in the scientific exhibits at the World Congress of Dermatology in Seoul, Korea in May 2011.

Poster Details:

A clinical study was conducted to determine if the biomimetic technology mimics the endogenous healing signal generated by the skin. CYTOMIMIC™ Technology, consisting of a proprietary galvanic coupling of elemental zinc and copper, was evaluated on the forearms of healthy males and females over the age of 18. The biomimetic signaling technology was compared to untreated skin, zinc oxide and zinc chloride. After cleansing, a small amount of each material was placed within defined 1.5mm diameter circles and measured for electric fields across the skin using a non-invasive instrument based on a vibrating probe technique. This technology has demonstrated anti-inflammatory activity and collagen and elastin production, as well as clinically proven safety and effectiveness in reducing the signs of photoaging.

"Bioelectricity is found in every single body system and cell in the body," says Dr. Sun. "Combining this knowledge with our innovative technology, we can potentially continue to expand and find new uses and platforms for CYTOMIMIC™ Technology to address countless additional needs in tissue repair applications."

The clinical study demonstrates that the topical application of biomimetic signaling technology to the skin provides an electric field profile similar to that of the endogenous electric field that the skin generates at a wound site.

This patented technology was discovered in 2004 by Dr. Sun and his colleagues Dr. Jue-Chen Liu and Jeannette Chantalat. Today, Johnson & Johnson Consumer Companies, Inc. holds 10 U.S. patents for this technology, active until 2023 and has multiple U.S. and international applications pending.